key: cord-0025167-kytb43nv
authors: Sundby, R. Taylor; Pan, Alex; Shern, Jack F.
title: Liquid biopsies in pediatric oncology: opportunities and obstacles
date: 2021-11-26
journal: Curr Opin Pediatr
DOI: 10.1097/mop.0000000000001088
sha: 8ec9a5b5e03b95b5900a3545cf889a6af1b58ad5
doc_id: 25167
cord_uid: kytb43nv

Liquid biopsies have emerged as a noninvasive alternative to tissue biopsy with potential applications during all stages of pediatric oncology care. The purpose of this review is to provide a survey of pediatric cell-free DNA (cfDNA) studies, illustrate their potential applications in pediatric oncology, and to discuss technological challenges and approaches to overcome these hurdles. RECENT FINDINGS: Recent literature has demonstrated liquid biopsies’ ability to inform treatment selection at diagnosis, monitor clonal evolution during treatment, sensitively detect minimum residual disease following local control, and provide sensitive posttherapy surveillance. Advantages include reduced procedural anesthesia, molecular profiling unbiased by tissue heterogeneity, and ability to track clonal evolution. Challenges to wider implementation in pediatric oncology, however, include blood volume restrictions and relatively low mutational burden in childhood cancers. Multiomic approaches address challenges presented by low-mutational burden, and novel bioinformatic analyses allow a single assay to yield increasing amounts of information, reducing blood volume requirements. SUMMARY: Liquid biopsies hold tremendous promise in pediatric oncology, enabling noninvasive serial surveillance with adaptive care. Already integrated into adult care, recent advances in technologies and bioinformatics have improved applicability to the pediatric cancer landscape.

First identified in 1948, cell-free DNA (cfDNA) has become a promising circulating biomarker in oncology [1, 2] . Developments in liquid biopsy, the capture of cfDNA, circulating proteins, and circulating tumor cells (CTCs), have led to adoption of technologies across stages of patient management including screening and diagnosis, molecular prognostication, tracking treatment response, detection of minimal residual disease (MRD), monitoring clonal evolution, and posttherapy surveillance [3] [4] [5] [6] [7] . The US Food and Drug Administration approved the first digital drop PCR (ddPCR) liquid biopsy tests in 2016, and two next generation sequencing (NGS) liquid biopsy panels in 2020 as companion diagnostics for associated targeted therapies [8] [9] [10] . As of the time of publication, no liquid biopsy tests have been Food and Drug Administration (FDA)approved in pediatrics.

Liquid biopsies are of particular interest for pediatric oncology as they are noninvasive, avoiding procedural sedation, and enabling serial sampling. Furthermore, liquid biopsies mitigate diagnostic challenges of tumor heterogeneity and accessibility by capturing genetic material shed throughout the body. This promise, however, comes with unique challenges that have limited wider implementation in pediatrics. Pediatric and adult cancers have differing genomic properties; pediatric cancers have low mutational burden [11] [12] [13] [14] with few recurrent hotspots [15 && ,16-20] . Adult cancers feature more point mutations [single nucleotide & ]. The portion of overall cfDNA constituted of ctDNA varies with cancer type, tumor location, tumor burden, and metastases. In low-burden and early disease, ctDNA fraction is minute [35, 36] . The detection of ctDNA, therefore, requires ultrasensitive methods that detect somatic variations. Thus, a broad understanding of the available technologies and evaluation of these considerations is necessary when selecting an approach for analyzing cfDNA.

PCR specifically amplify targeted cfDNA templates. To improve sensitivity and amplify a minute quantity of ctDNA, ddPCR technology subdivides PCR reactions into numerous nano-liter droplets, and can detect variant allele fractions (VAF) as low as 0.001% [7, 37] . Although ddPCR attains high sensitivities, it has limitations. First, it requires a priori knowledge of disease-specific or patient-specific mutations [37] , thereby missing any de novo mutations. Similarly, genome-wide surveys of translocations, indels, and CNA are limited, given the focused nature of the assay.

Next generation sequencing NGS methods do not require prior knowledge of mutations but have worse limits of detection than ddPCR and increased cost. The primary parameters affecting cost are breadth and depth of sequencing. Breadth is the proportion of the genome that is sequenced. NGS breadth varies from a panel of genes of interest (e.g. CAPPseq [38] ), to regions of the genome [e.g. whole exome sequencing (WES)], to the entire genome [whole genome sequencing (WGS)]. This gives NGS the capacity to detect both recurrent hotspot mutations and previously unknown or uncommon variants.

Depth refers to the average number of times a base pair is sequenced. Shallow WGS [e.g. 0.1-2x ultra-low pass WGS (ULP-WGS)] accurately detects CNAs [39] at low cost but has poor sensitivity for specific somatic variants. As depth increases, SNVs, indels, and translocations may be identified. However, as assay cost increases, deep-sequencing panels typically restrict breadth, focusing on smaller genomic regions and missing abnormalities outside of those regions.

Although previous methods identify genetic variations to characterize ctDNA, recent techniques leverage other ctDNA signatures. Pediatric cancer's low mutational burden may be better suited to alternative markers or combinatorial approaches. Methylation, for example, is a promising pediatric marker as epigenetic dysregulation is a recurrent characteristic of childhood cancers [40] . The circulating methylome can be measured in targeted cfMeDIP-seq [41] or ddMethyLight assays [42] as well as genome-wide approaches [43] . Methylation fingerprints may also define cfDNA tissues of origin [44, 45] . Emerging bioinformatic techniques, such as fragmentomics and transcriptomics, leverage nonrandom differences in cfDNA fragments and sequence coverage for in silico enrichment of ctDNA [33,34 & , 46] , and infer transcriptome profiles based on chromatin availability and nucleosome footprints [47] [48] [49] [50] 51 && ].

Liquid biopsies noninvasively capture cfDNA and circulating biomarkers shed from cancerous and healthy cells.

Liquid biopsies enable accurate molecular diagnostics and prognostication, tracking treatment response, detection of MRD, monitoring clonal evolution, and posttherapy surveillance.

Multiomic liquid biopsies hold promise for the overcoming the low-mutational burden challenge in pediatric cancers.

The diversity of assays available to profile cfDNA is matched by the range of potential applications for these tools in the clinic (Fig. 1 ).

Sequencing from multiple regions of the same tumor reveals significant intratumor genetic heterogeneity [52, 53] . Up to 69% of detected somatic mutations are absent from other regions of the same tumor [52], leading to potential sampling biases during biopsy. Liquid biopsy of cfDNA captures genetic materials released from multiple tissue regions and separate disease foci, mitigating sampling biases. Current adult clinical trials employ cfDNA for risk stratification and treatment selection [7, 54] . Liquid biopsy could similarly be used to inform management of pediatric cancers, guiding treatment intensification and de-escalation. Intralesional and interlesional heterogeneity of MYCN and ALK, for example, is well described in neuroblastoma [55, 56] . Accurate assessment of MYCN, ALK, and segmental chromosome alterations (SCA), has prognostic implications [57] [58] [59] and is incorporated into treatment selection. Intermediate-risk neuroblastoma patients without MYCN amplification or specific SCA maintain excellent outcomes with treatment reduction [60] ; therefore, genomic misclassification would lead to inappropriate de-escalation of treatment. Multiple studies demonstrate sensitive and tissue concordant molecular characterization of these genes and SCA in neuroblastoma using liquid biopsies [61] [62] [63] [64] [65] . The promise of liquid biopsy for risk stratification is further illustrated in pediatric sarcomas. In Ewing sarcoma (EWS) and osteosarcoma, the presence of detectable ctDNA alone predicts inferior outcomes. Furthermore, 8q gain in osteosarcoma cfDNA portended poorer 3-year event-free survival (EFS) (60 vs. 80.9%) [66] , and EWS high-risk co-mutations of STAG and TP53 [67] are detectable in cfDNA [68] .

Implementation of liquid biopsy for genomic characterization of Wilms tumor could reconcile international treatment paradigms. European consortium paradigms recommend neoadjuvant chemotherapy without tissue diagnosis because of the prevalence of favorable disease and risk of metastatic seeding with biopsy or surgery. In contrast, North American algorithms recommend upfront Liquid biopsies in pediatric oncology Sundby et al.

www.co-pediatrics.com nephrectomy for biology-guided therapy. In small studies, TP53 mutations were detectable in 100% of prenephrectomy urine cfDNA [69] and tumor-confirmed mutations were identified in plasma [70] . cfDNA profiles of poor prognosis TP53 mutations [71, 72] and 1p/16q alterations [70] , therefore, could guide therapy without risking seeding tumor.

Although mortality from primary pediatric cancers has decreased, intensification of treatments has led to increased treatment-related morbidity [73] . Clinical trials, therefore, have examined responseadapted protocols that reduce long-term morbidities in hematologic malignancies [74] [75] [76] . In pediatric solid tumors, response-adapted therapy is hindered by lack of serial biopsies; response markers are limited to imaging [77] , and necrosis estimates on postneoadjuvant resections [78] . Liquid biopsies offer noninvasive, serial monitoring to assess tumor burden, clonal evolution, and epigenetic changes. In a small osteosarcoma cohort, patients with more than 80% necrosis in resections had undetectable ctDNA following initiation of neoadjuvant therapy. Patients with less than 70% necrosis; however, had persistence of ctDNA throughout therapy [64] . Although larger validation studies are needed, these data suggest that ctDNA may predict prognostic postneoadjuvent percentage necrosis in osteosarcoma [78] . Similarly, dynamic changes in ctDNA have been shown to correlate with tumor burden in Wilms tumor [79] , hepatoblastoma [80] , retinoblastoma [81] [82] [83] , EWS [51 && ,77,84] , and neuroblastoma [61, 62] . Additionally, circulating epigenetic signatures approximate tumor burden and response. Data suggest that regional differences in coverage over DNase I hypersensitive sites (DHSs), a surrogate for chromatin status and epigenetic signatures [49, 51 && ], infer tissue type and can estimate tumor burden [51 && ]. Applebaum et al. measured epigenetic signatures using 5-hydroxymethylcytosine (5-hmC) to predict disease burden and response in metastatic neuroblastoma. 5hmC deposition on MYCN predicted relapse and end of induction total 5-hmC levels are prognostic. In two patients with no clinical evidence of disease, 5hmC profiling predicted subsequent relapse [85 ] . Finally, serial cfDNA can monitor clonal evolution and identify therapy-resistant subclones. A landmark study in lung cancer reported that cfDNA is more sensitive than tissue biopsy for detection of acquired resistance to erlotinib through EGFR T790M mutations [86] . In pediatrics, cfDNA temporally resolved heterogeneity in progressive neuroblastoma with a mean of 22 new SNV between diagnostic and subsequent samples, including 17 commonly acquired relapse-specific mutations [61] . Similarly, Barris et al. [87] identified TP53 mutations in relapsed osteosarcoma plasma not identified in initial tumor or germline. In medulloblastoma, dynamic changes in CSF cfDNA methylation mirror tissue changes during treatment and progression [43] .

Detection of minimum residual disease and posttherapy surveillance cfDNA's short half-life [29, 30] and representation of spatial heterogeneity [88] make it an ideal biomarker to detect postoperative minimum residual disease (MRD) and early recurrence. In adults, postoperative persistence of ctDNA portends a more than 80% risk of relapse in colorectal cancers [89] and urothelial carcinomas [90] . These findings suggest that ctDNA positivity postneoadjuvent therapy or surgery could inform clinical decisions regarding follow-up frequency and need for adjuvant or radiation therapy. Indeed, the addition of immunotherapy to urothelial carcinoma patients with postoperative ctDNA improved disease-free survival and overall survival [90] . Furthermore, application of cfDNA for MRD may enable earlier relapse detection. In lung cancer, recurrence of detectable ctDNA identified relapse a median of 5.2 months earlier than imaging [91] ; in colon and breast cancer, cfDNA outperforms biochemical biomarkers CEA and CA 15-3 for early, sensitive detection of recurrence [92, 93] .

To date, there have been no large MRD pediatric studies using cfDNA; however, case series demonstrate feasibility. Hayashi et al. used tumor-informed EWS-ETS ddPCR to detect fusion genes in plasma from three EWS patients. Two patients had persistent postoperative ctDNA and clinically relapsed. The only ctDNA-negative patient remained in remission [84] . In osteosarcoma, three of seven patients followed with targeted NGS liquid biopsy relapsed, all of whom had recurrence of detectable ctDNA prior to radiographic relapse [87] . Circulating mutant Rb1 becomes undetectable following enucleation of intraocular retinoblastoma [94, 95] but was again detectable in regionally recurrent or metastatic relapsed disease [83] . Finally, previously detectable circulating CTNNB1 in hepatoblastoma becomes undetectable following total resection with no histological or radiographic evidence of residual disease [80] .

Rapid technological advances coupled with exciting preliminary studies in pediatric histologies portend an important future for cfDNA in pediatric oncology; however, several important considerations must be considered in this population.

An assay's limit of detection is constrained by the number of unique sequencing reads generated. Each milliliter of blood has approximately 1000 genome equivalents [96] and sequencing to a depth greater than unique genome equivalents results in duplicated reads with no improvement in limits of detection [97 && ]. Theoretically, this presents a barrier in pediatrics because of weight-based limits in blood draw volume. Kahana-Edwin et al., however, highlight that the percentage of total blood volume collected during weight-based draws in pediatrics is consistent with adults. Furthermore, even earlystage pediatric cancers often represent a larger tumor burden relative to patient size than adult counterparts. Taken together, pediatric assays should capture a proportional or higher ratio of ctDNA:cfDNA because of relative tumor burden in similarly staged diseases [98] . Indeed, pediatric studies in neuroblastoma [65, 99] , EWS [66] , and hepatoblastoma [80] have demonstrated the feasibility of sensitive detection from less than 1 ml of plasma, and studies of unilateral intraocular retinoblastoma, characterized by exceptionally small tumor volumes, detect ctDNA in plasma [83, 100] .

An emerging challenge in liquid biopsies is false positives because of somatic mutations present in peripheral blood but not in tumor, termed clonal hematopoiesis of indeterminate potential (CHIP) [101] . A common phenomenon associated with aging, CHIP is the presence of a mutant clone in the blood without evidence of dysplasia, neoplasm, or cytopenia [102] . CHIP are attributed to survival advantages in certain mutations acquired during normal hematopoietic stem cell (HSC) divisions [103] . Studies of serial samples banked 10 years apart suggest that CHIP rarely undergo continued expansion [104] and have minimal risk of transforming into hematologic malignancy [105, 106] .

CHIP are classically defined as having a VAF of at least 2% [102] [103] [104] [105] 107] ; however, this threshold is based on previous limits of detection using WES [105] . Recent studies using error suppression algorithms suggest that CHIP accumulation likely begins in fetal development. 18.2% of sequenced cord blood samples harbor low frequency (VAF 0.002-0.006) somatic mutations [108] and, during normal hematopoiesis, individuals gain one mutation in HSCs per decade [103, 109] . It is hypothesized however, that these mutations do not confer survival advantages in youth [110] and, consequently, VAF of CHIP typically remains less than 0.5% until age 50 years [107, 111] . The VAF of CHIP in pediatrics, therefore, remains undetectable by many liquid biopsy assays [7, 39] . As technologies continue to push limits of detection in an effort to identify early-stage cancer, low-VAF CHIP may become a relevant source of false-positives in pediatric oncology. Multiomic or combinatorial imaging-cfDNA assays may mitigate this.

CHIP frequency increases in adults who received chemotherapy [105, 112, 113] and radiation therapy [105, 113] . These CHIP are enriched for TP53 mutations [113] , the most common somatically mutated gene in pediatric cancer [13] , presenting a potential source of false positives in posttherapy surveillance and MRD detection. The only study examining CHIP in pediatric cancer survivors, however, showed no increases using a 14-gene NGS panel [110] . Larger, longitudinal studies including broader panels or WGS with error suppression are necessary for validation.

With early-stage disease, increasing the number of targeted mutations improves probability of detection [5] . Pediatric cancers, however, have approximately one-fourteenth of the mutation burden of adult cancers [13] , with as few as one SNV per exome [12] , limiting targeted panels' utility in earlystage detection.

One strategy to improve probability of detection is to expand assayed targets by integrating 'multiomic' features including CNA [ ], protein [114] [115] [116] , and epigenetics [51 && ]. CNA is the most common alteration in pediatric solid tumors [13,15 && ,22] and may be inferred from off-target reads of targeted panels [117] or detected using ULP-WGS [34 & ,39, 81] . The utility of cfDNA CNA as a biomarker has been shown in neuroblastoma [61, 62, 65] , retinoblastoma [81, 82] , and EWS [64] , and the sensitivity of these assays can be boosted with fragmentomics [32,33,34 & ,46] . Our group reported that CNA combined with fragment size analysis not only detects malignancy but can accurately distinguish benign from malignant tumors in neurofibromatosis type 1 (NF1) [34 & ]. For small tumors, combinatorial assays with cfDNA and protein have doubled sensitivity in stage I/II pancreatic cancers and lesions measuring less than 1.5 cm [115] . Furthermore, pediatric cancers have a high incidence of mutations in epigenetic regulators [13,15 && ,118] . Integrating epigenetic and genetic signatures enabled accurate classification of sarcoma types [51 && ]. Finally, combinatorial approaches may not be multiomic but multimodality. Using a pan-cancer liquid biopsy for surveillance, Lennon et al. [119] increased their positive-predictive value by 45% after integrating imaging features.

Liquid biopsies have emerged as a noninvasive alternative to tissue biopsy. Despite the potential to allow serial molecular profiling while reducing invasive procedures and anesthesia events, implementation in pediatrics has been limited and liquid biopsy remains only a research tool. This is partly because of challenges presented by relatively low mutational burden. Multiomic strategies show promise for sensitive detection of low mutational burden disease but are expensive and require more blood for parallel assays. Exciting recent studies demonstrate that bioinformatic processing of 12x-35x WGS enables characterization of copy number analysis, small indels, fusions, chromatin accessibility, and detailed fragmentomics from a single assay (Fig. 2) ]. These novel approaches offer tremendous promise for childhood cancer by detecting the most common pediatric alterations in childhood cancers, incorporating multiomic input, and reducing required blood and cost.

Acknowledgements NIH Medical Arts created Fig. 1 . Images from BioRender were used to create Fig. 2 .

Financial support and sponsorship None. Recent studies have demonstrated that, with advanced bioinformatic analysis, WGS to depths of 12x-35x is sufficient for detection of copy number alterations, indels, translocations and fusions, assessment of chromatin accessibility and fragmentomics [51 && ,97 && ]. In addition to detecting the most common genomic alterations in childhood cancer, therefore, integration of these output also infers epigenetic and transcriptomic signatures. Combinatorial approaches, previously requiring multiple assays, enhance detection of early stage cancers.

There are no conflicts of interest.

Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest

Nuclear acids in human blood plasma

Isolation and characterization of DNA from the plasma of cancer patients

Assessment of circulating tumor DNA in pediatric solid tumors: the promise of liquid biopsies

Stå hlberg A. Circulating cell-free tumor DNA analysis in pediatric cancers

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Circulating tumor DNA analysis in patients with cancer

Application of cell-free DNA analysis to cancer treatment

Food and Drug Administration. cobas EGFR Mutation Test v2

FDA approves first liquid biopsy nextgeneration sequencing companion diagnostic test

Food and Drug Administration. FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers

fda-approves-liquid-biopsy-ngscompanion-diagnostic-test-multiple-cancers-and-biomarkers

Cancer genome landscapes

Mutational heterogeneity in cancer and the search for new cancer-associated genes

The landscape of genomic alterations across childhood cancers

Comprehensive analysis of hypermutation in human cancer

Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing

This study uses a multiomic approach (WGS, WES, RNAseq) to examine tumor and germline from pediatric cancers. The authors demonstrated that, in tissue, combinatorial approaches are necessary to identify the full range of genomic variants in childhood cancer

Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA

Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer

Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer

Quantitative cellfree circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing

Mutational landscape and significance across 12 major cancer types

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

The genomic landscape of pediatric cancers: Implications for diagnosis and treatment

Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR

Integrating liquid biopsies into the management of cancer

Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine

Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study

Rapid clearance of fetal DNA from maternal plasma

Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma

Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients

Enhanced detection of circulating tumor DNA by fragment size analysis

Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study

This is the first study use cfDNA to identify malignancy in a cancer predisposition syndrome. Copy number analysis with fragmentomics distinguished benign from malignant tumors and cfDNA profiles recapitulated characteristic tissue genomic alterations

Circulating mutant DNA to assess tumor dynamics

Detection of circulating tumor DNA in early-and late-stage human malignancies

Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Developmental origins and emerging therapeutic opportunities for childhood cancer

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Blood-based detection of colorectal cancer using cancer-specific DNA methylation markers

Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma

Plasma DNA tissue mapping by genomewide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

Applications of genetic-epigenetic tissue mapping for plasma dna in prenatal testing, transplantation and oncology

Genome-wide cell-free DNA fragmentation in patients with cancer

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma

Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin

Nonrandom fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation

Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

Advanced fragmentomic analyses are introduced for classification of low mutation burden cancers. Finally, the authors use integrated genetic/epigenetic analysis to sensitively detect and distinguish between various pediatric sarcomas

Intratumor heterogeneity: evolution through space and time

Circulating tumour DNA (ctDNA) analysis informing adjuvant chemotherapy in Stage II Colon Cancer

Deep sequencing reveals occurrence of subclonal alk mutations in neuroblastoma at diagnosis

Heterogeneity of the MYCN oncogene in neuroblastoma

Overall genomic pattern is a predictor of outcome in neuroblastoma

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

Maintaining outstanding outcomes using response-and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children's Oncology Group study ANBL0531

Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatmentresistant clones in neuroblastoma

Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma

Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors

Neuroblastoma molecular risk-stratification of DNA copy number and ALK genotyping via cell-free circulating tumor DNA profiling

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group

Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations

Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas

Somatic TP53 mutations are detectable in circulating tumor DNA from children with anaplastic Wilms tumors

Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children's Oncology Group AREN0533 Study

Significance of TP53 mutation in Wilms tumors with diffuse anaplasia: a report from the Children's Oncology Group

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia

Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group

Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study

Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcoma

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate

Assessment of somatic mutations in urine and plasma of Wilms tumor patients

Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma

Cell-free DNA tumor fraction in the aqueous humor is associated with therapeutic response in retinoblastoma patients

Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma

Retrospective evaluation of somatic alterations in cell-free DNA from blood in retinoblastoma

Highly personalized detection of minimal ewing sarcoma disease burden from plasma tumor DNA

5-Hydroxymethylcytosine profiles in circulating cell-free DNA associate with disease burden in children with neuroblastoma

This study demonstrates that epigenetic signatures in cfDNA are a viable marker for risk stratification and prognostication in pediatric cancers. The authors approximate tumor burden and predict risk of relapse in neuroblastoma

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

Detection of circulating tumor DNA in patients with osteosarcoma

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pretreated metastatic cancer

Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Analysis of circulating tumor DNA to monitor metastatic breast cancer

Retinoblastoma: saving life with vision

Advanced unilateral retinoblastoma: the impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC

Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

This study describes how the current paradigm of deep sequencing of cfDNA with targeted panels is limited in low-disease burden settings by low tumor fraction with few unqiue genomic equivlanets. They demonstrate that modest depth (35x) WGS improves sensitivity by increasting breadth to integrate the cumulative signals of multiple genomic features and alterations

Roadmap to liquid biopsy biobanking from pediatric cancers-challenges and opportunities

Opportunities and challenges of circulating biomarkers in neuroblastoma

Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: an MSKCC experience

False-positive plasma genotyping due to clonal hematopoiesis

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

Germline risk of clonal haematopoiesis

Clonal hematopoiesis and risk of acute myeloid leukemia

Clonal hematopoiesis of indeterminate potential: an expanding genetic cause of cardiovascular disease

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Inherited causes of clonal haematopoiesis in 97,691 whole genomes

Error-corrected sequencing of cord bloods identifies pediatric AML-associated clonal hematopoiesis

The origin and evolution of mutations in acute myeloid leukemia

Clonal haematopoiesis is not prevalent in survivors of childhood cancer

Detectable clonal mosaicism from birth to old age and its relationship to cancer

Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Comprehensive identification and characterization of human secretome based on integrative proteomic and transcriptomic data

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

Detection and localization of surgically resectable cancers with a multianalyte blood test

Evaluation of copy number variant detection from panel-based next-generation sequencing data

The landscape of somatic mutations in epigenetic regulators across 1000 pediatric cancer genomes

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention